APOE and Cognitive impairment: Inversely, APOE4 carrier status was associated with a 34% (95% CI: 24–45%) increased risk of objective cognitive impairment only in those with low-impact or no pain, and this relationship was maintained after multivariable and multiple comparison adjustment (aHR = 1.46, 95% CI: 1.36, 1.57).